Background
While renin-angiotensin system inhibitors (RASi) have shown benefits for people with both heart failure (HF) and chronic obstructive pulmonary disease (COPD), limited data exists on the use of angiotensin receptor-neprilysin inhibitors (ARNIs) in this population. This study compares the effectiveness of RASi and ARNIs in people with coexisting COPD and HF.
Methods
We identified individuals who started treatment with either ARNI or RASi since August 1, 2015. We assessed outcomes such as COPD exacerbations, acute respiratory failure, and lower respiratory tract infections (LRTIs) over 30 days to 3 years. Kaplan-Meier survival analysis and Cox regression models were applied to estimate survival probabilities and hazard ratios (HR).
Results
Among 9,071 ARNI users and 71,836 RASi users, the ARNI group has fewer respiratory complications. The ARNI group has a higher proportion of females compared to the RASi group (38.2% vs. 31.5%). Specifically, ARNI users have a lower incidence of COPD exacerbations (13.1% vs. 18.7%; HR, 0.84), acute respiratory failure (16.2% vs. 22.0%; HR, 0.90), and LRTIs (16.9% vs. 22.9%; HR, 0.91).
Leave a Reply